Previous studies had confirmed that ChREBP promoted lipid synthesis via mediating its target gene expression [acetyl CoA carboxylase (ACC) and fatty acid synthase (FAS)] and then led to NAFLD (22). The gene discussed is FASN; the disease is metabolic dysfunction-associated steatotic liver disease.